Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02485704
Recruitment Status : Completed
First Posted : June 30, 2015
Results First Posted : January 16, 2019
Last Update Posted : January 16, 2019
Sponsor:
Collaborator:
Concentrics Research
Information provided by (Responsible Party):
ParaPRO LLC

Brief Summary:
To assess the safety and efficacy of Natroba (spinosad) topical suspension versus placebo for the complete cure of scabies after a single treatment.

Condition or disease Intervention/treatment Phase
Scabies Drug: spinosad topical suspension, 0.9% Other: Placebo Phase 3

Detailed Description:

This is a double blind, two-arm, 28-day, placebo-controlled study with approximately 120 infested "index" subjects randomized 1:1 to Natroba™ or Placebo. All members of a household (no more than 6 individuals) with a suspected "index" subject must be screened at the first visit. In this study, "index" subjects are defined as the youngest infested household member (≥4 years). If the members have an active scabies infestation and meet all other criteria, they must agree to participate in the study. Household members who do not present with scabies at the screening visit must also agree to apply the same blinded investigational product (IP) as household members who present with scabies. All infested household members must agree to participate in the study or none will be enrolled. Screening procedures include informed consent, medication and medical history, urine pregnancy test for females of childbearing potential, scabies assessment (visual evidence of burrows, inflammatory/non-inflammatory lesions and pruritus), microscopic examination of skin scraping, or dermatoscopy, to demonstrate the presence of mites, eggs, and/or scybala (dermatoscopy must confirm burrows), vital signs, general skin and eye assessment, randomization, and IP dispensing and instruction.

After screening on Day 1, all randomized subjects will be dispensed IP (Natroba™ or Placebo) to apply at home later the same day as a single treatment over the entire body from the neck down to the toes (including the soles of the feet) and to the scalp (if balding) or hairline, temples and forehead on the same day. Subjects less than 12 years of age should be assisted with administration by a parent, guardian or caregiver. Subjects will rub the treatment into the skin followed by a 10-minute wait period before getting dressed. Showering or bathing must not occur earlier than 6 hours after treatment and no later than at least 1 hour prior to Day 2 visit.

On Day 2 (Visit 2), all household members will return for general skin and eye assessments of possible irritation, and to confirm that all IP was left on for a minimum of 6 hours before bathing or showering. If a subject reports an adverse event assessed as related by the PI on Day 2 (Visit 2) then a follow-up visit with the investigator must be scheduled within 7 days of visit. All household members will receive a well-being phone call on Day 14 to continue to emphasize instructions to prevent re-infestation, determine if any concomitant medications have been used, and check for adverse events. If a subject reports an adverse event assessed as related by the PI on the Day 14 well-being phone call, then a follow-up visit with the investigator must be scheduled within 7 days of phone call.

On Day 28 (Visit 3), all household members will return to the clinic for safety and efficacy assessments. The primary endpoint of complete cure will be assessed in the "index" subject and any infested household members. If the infested subject is completely cured at Day 28, he or she will have completed the study and termination procedures will be conducted. If the subject is not completely cured at Day 28 (with Natroba™ or Placebo), the subject will receive 5% Permethrin and will be directed to their primary care physician for follow-up.

Safety assessments will be made for all household members and will include monitoring of adverse events (AEs) throughout the study, vital signs recording (Days 1 and 28), clinical laboratory analyses (Days 1 and 28), and general skin and eye irritation assessments (Days 1, 2, and 28). The Day 28 procedures will also be completed for early termination (ET) except subjects will not receive rescue Permethrin but will be directed to follow-up with their primary care physician.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 280 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Natroba™ (Spinosad) for the Treatment of Scabies
Actual Study Start Date : May 10, 2017
Actual Primary Completion Date : August 3, 2018
Actual Study Completion Date : August 3, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Scabies
Drug Information available for: Spinosad

Arm Intervention/treatment
Experimental: Natroba (spinosad)
spinosad topical suspension, 0.9% up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours
Drug: spinosad topical suspension, 0.9%
Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
Other Name: Natroba (spinosad) Topical Suspension, 0.9%

Placebo Comparator: Placebo
placebo is a topical suspension that is the same formulation as Natroba without the active ingredient spinosad (vehicle). Up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours.
Other: Placebo
Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.




Primary Outcome Measures :
  1. Number of Index Subjects Completely Cured of Scabies After a Single Treatment [ Time Frame: 28 days after treatment ]
    The primary efficacy assessment is the proportion of index subjects completely cured of scabies by Day 28. Complete cure is defined as a demonstration of both clinical cure (all signs and symptoms have completely resolved, including burrows, inflammatory/non-inflammatory lesions and pruritus) and microscopic or dermatoscopic cure demonstrating the absence of mites, eggs, and/or scybala, and a negative dermatoscopy for burrows.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   4 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All household members who have provided written informed consent and an authorization for disclosure of protected health information must meet all the following criteria:

    1. Male or female, age 4 years and upward.
    2. At least one household member must have active scabies infestation confirmed by clinical signs and symptoms (evidence of burrows or presence of scabies inflammatory/non-inflammatory lesions and pruritus) as well as by microscopic examination of skin scraping, or dermatoscopy, to demonstrate the presence of mites, eggs, and/or scybala. If dermatoscopy is used it should also confirm there are burrows on the skin.
    3. Generally in good health based on medical history and clinical assessments.
    4. Normal-appearing skin in noninfested areas.
    5. No history of chronic or recurrent dermatologic disease.
    6. Willingness to comply with the study procedures including application of study treatment at home as instructed.
    7. Willing and able to practice an acceptable measure of contraception during the study, if female of childbearing potential. Examples of acceptable contraceptive methods include abstinence, intrauterine device (IUD), double barrier method, oral or implantable or injectable contraceptives. Must have been using systemic (oral, injectable, or implantable) contraceptives for at least 3 months. If abstinent and planning to become sexually active must agree to use a double barrier method.
    8. Subject agrees to inform their sexual partners to seek an examination for scabies and treatment if, and when, symptoms present.
    9. Household members must be 6 or fewer and all members must be willing to attend clinic visits and be randomized to treatment (blinded, but same for all).

Exclusion Criteria:

  • All household members must be excluded if any of the following conditions are met:

    1. Household has greater than 6 residents.
    2. Has a household member(s) who is not willing or not eligible to enroll.
    3. Presence of scabies on the scalp.
    4. Presence of crusted scabies (Norwegian scabies).
    5. Allergies or intolerance to ingredients in the IPs.
    6. Current pregnancy (as assessed by urine pregnancy test) or currently nursing.
    7. The household has sexually active subjects who do not agree to restrict prolonged skin to skin contact with non-household members during the trial period.
    8. Known renal or hepatic impairment.
    9. Treatment with scabicide within the prior 4 weeks.
    10. Immunodeficiency (including HIV infection) as reported by the subject in Medical History.
    11. Signs or symptoms of systemic infection.
    12. Administration of any systemic therapy for infectious disease within the prior 2 weeks.
    13. Receipt of any other investigational product (IP) within the prior 4 weeks.
    14. Any other conditions that, at the investigator's discretion, may interfere with the study conduct, or which might confound the interpretation of the study results, or which may put the subject at undue risk.
    15. Does not have a known household affiliation with their household members (stays in one household inconsistently, i.e., sleeps at one place several nights and then other places on other nights).
    16. Household member is unwilling to treat scabies.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02485704


Locations
Layout table for location information
United States, California
Saint Joseph's Clinical Research
Anaheim, California, United States, 92804
Long Beach Clinical Trial Services
Long Beach, California, United States, 90806
United States, Florida
The Chappel Group Research
Kissimmee, Florida, United States, 34744
United States, Pennsylvania
DermDox Centers for Dermatology
Hazleton, Pennsylvania, United States, 18201
Paddington Testing Company
Philadelphia, Pennsylvania, United States, 19103
United States, Texas
West Houston Clinical Research Service
Houston, Texas, United States, 77055
Discovery Clinical Trials
McAllen, Texas, United States, 78503
Sponsors and Collaborators
ParaPRO LLC
Concentrics Research
Investigators
Layout table for investigator information
Study Director: Kerry W Mettert, MBA ParaPRO LLC
  Study Documents (Full-Text)

Documents provided by ParaPRO LLC:
Study Protocol  [PDF] March 23, 2018
Statistical Analysis Plan  [PDF] August 24, 2018


Layout table for additonal information
Responsible Party: ParaPRO LLC
ClinicalTrials.gov Identifier: NCT02485704    
Other Study ID Numbers: SPN-304-15
First Posted: June 30, 2015    Key Record Dates
Results First Posted: January 16, 2019
Last Update Posted: January 16, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Scabies
Mite Infestations
Ectoparasitic Infestations
Skin Diseases, Parasitic
Parasitic Diseases
Skin Diseases, Infectious
Skin Diseases